C7orf25

Across TCGA pan-cancer cohorts, C7orf25 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C7orf25 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher C7orf25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C7orf25 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, SARC, and LIHC are the cancer types where C7orf25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.181	0.742	.007	15	view →
SARC	DFS	Median	All	0.096	0.632	.003	12	view →
LIHC	DFS	Median	All	0.107	0.555	.005	9	view →
UCEC	DFS	Median	All	0.965	0.621	.012	8	view →
COAD	OS	Median	II,III,IV	0.111	0.851	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C7orf25–LUSC (OS)

Open the LUSC breakdown →